Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
cancer immunotherapy
7
×
clinical trials
7
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
7
×
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
startups
7
×
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
cancer
fda
deals
nonalcoholic steatohepatitis
abbvie
biogen
bristol-myers squibb
eli lilly
investing
alzheimer's disease
What
roundup
bio
drug
biotech
nash
news
annual
attention
companies
days
disease
growing
according
acquisitions
ahead
akcea
alliance
alzheimer’s
ambien
american
announced
approval
approved
asco
assessed
attendees
biogen’s
biopharmaceutical
bristol
buy
calls
camp’s
cancer
cases
cash
centers
ceo
changing
chicago
cigarettes
Language
unset
Current search:
startups
×
" indiana top stories "
×
" cancer immunotherapy "
×
" clinical trials "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More